The chief executive and medical director of Fast Lab Technologies allegedly engaged in a $500 million fraud scheme involving COVID-19 tests, the U.S. Department of Justice (DOJ) said. Fast Lab CEO ...
Drug research and manufacturing used to be more “one-size-fits-all” — with small pipelines, big batches, and global distribution. But cell and gene therapies, antibodies, and other advanced drugs are ...
LONDON, Dec. 1, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX) announced today that the intended use for its Food and Drug Administration (FDA) Emergency Use Authorization (EUA) SARS-CoV-2 RNA STAR ...
LONDON, June 8, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX) today announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results